SWOG (formerly the Southwest Oncology Group) has chosen Sequenta's LymphoSIGHT platform for the measurement of minimal residual disease (MRD) in 180-patient mantle cell lymphoma clinical trial.
The patients in the SWOG S1106 mantle cell lymphoma trial will undergo testing for MRD during treatment and for up to three years of clinical follow up using Sequenta's LymphoSIGHT platform.
Sequenta will carry out sequencing analysis on peripheral blood and bone marrow samples from the study. Additionally, imaging studies will be used to measure disease progression.
Sequenta CEO Tom Willis said, "The selection of our LymphoSIGHT platform for use in this trial represents a significant step toward making our technology the clinical standard for sensitive MRD detection."
The LymphoSIGHT method leverages an assay for the amplification and sequencing of immunoglobulin and T cell receptors, allowing ultra sensitive detection and monitoring of T and B cells.
The next generation sequencing is used by the platform to detect individual B cells at levels as low as one cell per million white blood cells using a universal reagent set and routinely available blood samples.
